Explore this article's sources with AI
Follow PeptideMethods on Google
Reading the Semaglutide Aspiration Reply
The semaglutide reply confirms scientific correspondence, but its indexed record contains no argument, rebuttal, or new patient data.
Why we wrote this. The reply's title invites overreading. We separate what its metadata proves from the clinical findings reported in the original study.
In this article (6 sections)
A new Anaesthesia record titled "Gastric content and aspiration risk after semaglutide cessation: a reply" confirms that scientific correspondence followed a 2026 gastric-ultrasound study. The reply is indexed as a Letter, with a publication date and DOI but no abstract or full text in PubMed.[1] That record establishes that the authors replied. It does not reveal the comment's argument, the authors' answer, or any new patient result. The clinical numbers below come from the original study, not the reply.
What the letter records establish
PubMed lists the reply by Nils Vlaeminck, Vera Saldien and Peter Van de Putte. It was published online on 14 August 2026 in Anaesthesia and carries DOI 10.1111/anae.70328. Its publication type is Letter.[1] The record contains no abstract and no PubMed Central identifier. Those omissions prevent a responsible summary of the reply's reasoning.
A separate PubMed record lists Yue Chang's item, "Gastric content and aspiration risk after semaglutide cessation," as a Letter in the same journal issue. That record also has no abstract.[2] A title can identify the subject of correspondence, but it cannot establish whether the letter challenged the study design, disputed an estimate, asked for clarification, or raised a different concern. The existence of a reply does not show that an error was found or corrected.
The study behind the exchange
The accessible evidence comes from the original paper, "Gastric ultrasound in patients receiving semaglutide." This was a prospective, multicentre, matched case-control study in people having elective surgery. Investigators enrolled 44 people receiving semaglutide for diabetes or weight loss and 44 controls matched on age, body mass index and diabetes status. They used ultrasound in two body positions after pre-operative fasting.[3]
The researchers defined a "full stomach" as visible solid content in either position or a calculated gastric volume above 1.5 millilitres per kilogram of total body weight in the right lateral position. One semaglutide participant did not contribute the relevant analysis, leaving 43 people in that group for the reported comparison.[3] This definition is an ultrasound threshold used to assess residual gastric content. It is not a record of material entering a patient's airway or lungs.
What the 49% finding means
A full stomach was found in 21 of 43 semaglutide participants, or 49%, compared with 8 of 44 controls, or 18%. The reported odds ratio was 4.29, with a 95% confidence interval from 1.63 to 11.29. Solid gastric content was present in 18 of 43 semaglutide participants, or 42%, and 3 of 44 controls, or 7%.[3] The study found no statistically significant difference in calculated gastric volume.
These findings concern retained stomach contents after fasting. The study abstract does not report pulmonary aspiration events, nor was aspiration the measured comparison. Residual gastric content can contribute to aspiration risk under general anaesthesia or deep sedation, but a risk marker and a clinical event are different outcomes. The MHRA describes retained content as a reason for individual peri-operative risk assessment, while noting that the evidence did not support one specific pause interval for the whole drug class.[4]
What cessation does not settle
The original paper's abstract says the elevated ultrasound finding persisted after one administration had been withheld.[3] It does not present a randomized comparison of several stopping intervals. The study therefore cannot tell readers that a fixed number of days eliminates retained gastric content, and the inaccessible reply cannot be used to fill that gap. A calendar interval may be one part of an anaesthesia plan, but this paper does not validate a universal interval.
The MHRA reached a similarly narrow regulatory position in January 2025. Its review supported an association between GLP-1 medicines and potential pulmonary aspiration during anaesthesia or deep sedation because these medicines delay gastric emptying. It also said evidence was limited for recommending a specific pause time, a new fasting rule, or one procedure to confirm an empty stomach.[4] That agency guidance concerns the drug class and clinical risk management. It does not disclose what either Anaesthesia letter argued.
What the reply cannot yet support
The available reply record cannot support claims that the authors rebutted Chang's concern, defended a particular cessation schedule, revised the 49% estimate, or reported another cohort. None of those propositions appears in the indexed metadata.[1] The same limit applies in the other direction: the comment's abstract-free record cannot show that it identified bias, proved a longer drug hold was necessary, or documented an aspiration event.[2]
This distinction also keeps the new article separate from the original trial readout. The paper supplies observational ultrasound data from a matched surgical population. The two later records supply evidence that correspondence occurred. Until the letters themselves are accessible, the original study remains the source for its design and estimates, and the reply remains bibliographic evidence rather than a second clinical dataset.[3]
What patients can take from this
People using semaglutide who have an upcoming procedure should tell the surgical and anaesthesia teams about the medicine. The MHRA advises patients not to stop prescribed treatment without first discussing it with their doctor, and it asks anaesthetists to assess aspiration risk individually.[4] Our semaglutide safety overview provides background on the medicine. It cannot replace a procedure-specific plan from the treating team.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Does the semaglutide reply report new patient data?
Not in the accessible record. PubMed indexes the reply as a Letter and provides bibliographic metadata, but no abstract, full text, or new patient dataset.
What did the original gastric ultrasound study find?
The matched observational study reported a full stomach in 49% of analyzed semaglutide participants and 18% of controls after fasting. It measured residual gastric content, not aspiration events.
How long should semaglutide be stopped before surgery?
This study did not compare several stopping intervals, and the indexed reply does not answer that question. Patients should not stop prescribed treatment without discussing the procedure with their doctor and anaesthesia team.
Sources
- [1]Vlaeminck N, Saldien V, Van de Putte P. Gastric content and aspiration risk after semaglutide cessation: a reply. Anaesthesia. 2026. PMID 42601802.Tier 1 · primary↩
- [2]Chang Y. Gastric content and aspiration risk after semaglutide cessation. Anaesthesia. 2026. PMID 42608018.Tier 1 · primary↩
- [3]Vlaeminck N et al. Gastric ultrasound in patients receiving semaglutide: a prospective, multicentre, matched control study. Anaesthesia. 2026. PMID 41631344.Tier 1 · primary↩
- [4]MHRA. GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during anaesthesia or deep sedation.Tier 1 · primary↩
No revisions yet. First published .